To hear about similar clinical trials, please enter your email below
Trial Title:
Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma
NCT ID:
NCT05759858
Condition:
Hepatocellular Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular
Conditions: Keywords:
Hepatocellular carcinoma
Genomes
Prognosis
Gene targeted therapy
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
None of intervention
Description:
None of the interventions was applied.
Arm group label:
Patients with hepatocellular carcinoma confirmed by pathology.
Summary:
To explore the key genes of human and mouse hepatocellular carcinoma, identify the key
genes and prognostic markers, and develop small molecule drugs targeting the key genes to
treat hepatocellular carcinoma.
Detailed description:
Hepatocellular carcinoma (HCC) is one of the most common solid malignant tumors and the
main cause of cancer-related deaths worldwide. About 750000 new cases of liver cancer are
diagnosed every year, half of which are in China. The onset of liver cancer is relatively
hidden, and there are generally no symptoms in the early stage. When the patient has
obvious clinical symptoms, the disease often belongs to the middle and late stages. The
first symptom of liver cancer is liver pain, followed by upper abdominal mass. Some
patients also showed some complications of liver cirrhosis, such as black stool,
hematemesis, jaundice, liver coma, ascites, etc. A few patients were hospitalized due to
symptoms caused by metastatic lesions.
At present, the accuracy of detecting HCC is poor, and the common indicators such as AFP
have a certain time lag, which cannot detect patients with liver cancer early. thus,
there is an urgent need for a new biomarker for the diagnosis and prognosis of liver
cancer. Our research focuses on exploring the key genes of human and mouse hepatocellular
carcinoma, identifying the key genes and prognostic markers by means of transcriptome
sequencing, and developing small molecule drugs targeting the key genes.
High-throughput sequencing technology was used for sequencing analysis to reflect the
expression level of mRNA, small RNA, noncoding RNA, or some other markers. After finding
the gene difference between the liver cancer sample and the para-cancer sample, relevant
immunohistochemical staining was performed to analyze the overall survival time
difference between the patients with high-expression genomes and the patients with
low-expression genomes. Follow-up cell and animal experiments were carried out to further
verify the effect of target genes on the occurrence and development of liver cancer. In
the first month after the operation, the patient was followed up at the outpatient clinic
to understand the general situation of the patient after the operation, such as diet and
appetite, symptom control, such as fever, abdominal pain, and drainage tube removal. One
year and three years after the operation, our center will follow up on the patients and
re-hospitalization if necessary.
Criteria for eligibility:
Study pop:
Patients suffered hepatocellular carcinoma which was confirmed by pathology. Only
surgical treatment is applied to patients.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
1. Hepatocellular carcinoma confirmed by pathology;
2. The patient has no combined organic diseases of heart, lung, and kidney, etc;
3. No history of chemotherapy, radiotherapy, upper abdominal surgery, or combined with
other tumors;
4. The patient has successfully completed the operation and has complete clinical
information and pathological data.
Exclusion Criteria:
1. Patients who have previous history of other tumors or have undergone upper abdominal
surgery;
2. Patients with multiple lesions and distant metastasis;
3. Patients who are complicated with organic diseases of important organs such as
heart, lung and kidney and cannot tolerate surgery；
4. Patients who are more than 75 years old or less than 18 years old.
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Address:
City:
Hangzhou
Country:
China
Status:
Recruiting
Contact:
Last name:
Yang Tian, Doctor
Phone:
15088673780
Contact backup:
Last name:
Yuancong Jiang, Doctor
Phone:
18868107327
Email:
jiangyuancong@zju.edu.cn
Start date:
December 14, 2022
Completion date:
December 2025
Lead sponsor:
Agency:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Agency class:
Other
Source:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05759858
